Calreticulin arms NK cells against leukemia
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F20%3A10410883" target="_blank" >RIV/00216208:11130/20:10410883 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/20:10410883
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ID7MgkO.RP" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ID7MgkO.RP</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/2162402X.2019.1671763" target="_blank" >10.1080/2162402X.2019.1671763</a>
Alternative languages
Result language
angličtina
Original language name
Calreticulin arms NK cells against leukemia
Original language description
Calreticulin (CALR) exposed on the surface of cancer cells succumbing to therapy delivers robust phagocytic signals that support the activation of adaptive anticancer immune responses. Recent data from our group demonstrate that spontaneous CARL exposure on leukemic blasts also supports innate anticancer immunity by natural killer (NK) cells via an indirect mechanism relying on myeloid CD11c(+)CD14(+) cells.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
30102 - Immunology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů